Suppression of the SDF‑1/CXCR4/β‑catenin axis contributes to bladder cancer cell growth inhibition in vitro and in vivo

Zhang,Tao; Yang,Fei; Li,Wenbiao; Liu,Bolong; Li,Wende; Chen,Zhiyi; Wang,Can

doi:10.3892/or.2018.6546

Suppression of the SDF‑1/CXCR4/β‑catenin axis contributes to bladder cancer cell growth inhibition in vitro and in vivo

Authors:
- Tao Zhang
- Fei Yang
- Wenbiao Li
- Bolong Liu
- Wende Li
- Zhiyi Chen
- Can Wang
View Affiliations

Affiliations: Department of Urology, Beijing University of Chinese Medicine Shenzhen Hospital, Shenzhen, Guangdong 518172, P.R. China, Department of Urology, The Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China, Guangdong Laboratory Animals Monitoring Institute, Guangzhou, Guangdong 510260, P.R. China, Department of Urology, Beijing University of Chinese Medicine Shenzhen Hospital, Shenzhen, Guangdong 518172, P.R. China
Published online on: July 4, 2018 https://doi.org/10.3892/or.2018.6546
Pages: 1666-1674

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have found that the activation of stromal cell‑derived factor‑1 (SDF‑1)/CXC chemokine receptor‑4 (CXCR4)/β‑catenin signaling is associated with biological malignant potential in cancers. However, its function has been rarely reported in the progression of bladder cancer (BCa). The aim of the present study was to investigate the association of SDF‑1/CXCR4 signaling and β‑catenin in regards to BCa cell proliferation, colony formation, migration and invasion. The methods used were MTS, colony formation, and Transwell migration and invasion assays which were performed in SW780 cells following treatment with the CXCR4 antagonist AMD3465, SDF‑1, the β‑catenin antagonist FH535, AMD3465+SDF‑1 or FH535+SDF‑1. The mRNA and protein levels were assayed by RT‑qPCR and western blotting, respectively. The effect of AMD3465 on SW780 cell xenograft growth in vivo was evaluated using a nude mouse model. According to our results, human BCa SW780 cells were identified as having high expression of CXCR4 and β‑catenin. Subsequently, we found that both CXCR4 and β‑catenin antagonists could significantly inhibit the proliferation, colony formation, migration and invasion of SW780 cells. Notably, SDF‑1 could reverse the inhibitory effects of AMD3465 and FH535 on proliferation, colony formation, migration and invasion in SW780 cells. In AMD3465‑treated SW780 cells, the expression of c‑myc was significantly upregulated, and E‑cadherin was downregulated in the presence of SDF‑1. Furthermore, the tumor volume and average weight in the AMD3465‑treated group were evidently less than these parameters in the control group, indicating that AMD3465 can inhibit SW780 cell growth in vivo. In conclusion, targeting the SDF‑1/CXCR4/β‑catenin axis may be a potential therapeutic target for suppressing BCa progression.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A and Frenkel E: Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer. 117:276–282. 2011. View Article : Google Scholar : PubMed/NCBI
4	Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, Bellmunt J, Peters F, Le-Guennec S, Cerbone L, et al: Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: A randomized, active-controlled, phase III trial (CILAB). Oncology. 85:208–215. 2013. View Article : Google Scholar : PubMed/NCBI
5	Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D and Jain RK: CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies? Clin Cancer Res. 17:2074–2080. 2011. View Article : Google Scholar : PubMed/NCBI
6	Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931. 2010. View Article : Google Scholar : PubMed/NCBI
7	Meads MB, Hazlehurst LA and Dalton WS: The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 14:2519–2526. 2008. View Article : Google Scholar : PubMed/NCBI
8	Zheng N, Chen J, Liu W, Liu J, Li T, Chen H, Wang J and Jia L: Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1/CXCR4 chemokine axis. Oncotarget. 8:59123–59135. 2017.PubMed/NCBI
9	De-Colle C, Menegakis A, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, et al: SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiother Oncol. 126:125–131. 2018. View Article : Google Scholar : PubMed/NCBI
10	Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Okugawa Y, Kawamoto A, Yasuda H, Inoue Y, Miki C and Kusunoki M: Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol. 17:2051–2058. 2010. View Article : Google Scholar : PubMed/NCBI
11	Hinton CV, Avraham S and Avraham HK: Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis. 27:97–105. 2010. View Article : Google Scholar : PubMed/NCBI
12	Li X, Li P, Chang Y, Xu Q, Wu Z, Ma Q and Wang Z: The SDF-1/CXCR4 axis induces epithelial-mesenchymal transition in hepatocellular carcinoma. Mol Cell Biochem. 392:77–84. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wang B, Wang W, Niu W, Liu E, Liu X, Wang J, Peng C, Liu S, Xu L, Wang L, et al: SDF-1/CXCR4 axis promotes directional migration of colorectal cancer cells through upregulation of integrin αvβ6. Carcinogenesis. 35:282–291. 2014. View Article : Google Scholar : PubMed/NCBI
14	Guo Q, Gao BL, Zhang XJ, Liu GC, Xu F, Fan QY, Zhang SJ, Yang B and Wu XH: CXCL12-CXCR4 axis promotes proliferation, migration, invasion, and metastasis of ovarian cancer. Oncol Res. 22:247–258. 2014. View Article : Google Scholar : PubMed/NCBI
15	Eisenhardt A, Frey U, Tack M, Rosskopf D, Lümmen G, Rübben H and Siffert W: Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol. 47:111–117. 2005. View Article : Google Scholar : PubMed/NCBI
16	Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, Rosser CJ, Soloway MS and Lokeshwar VB: Differential expression of SDF-1 isoforms in bladder cancer. J Urol. 191:1899–1905. 2014. View Article : Google Scholar : PubMed/NCBI
17	Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, Carroll P, Simko J, Waldman FM and Basbaum C: CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer. 114:182–189. 2005. View Article : Google Scholar : PubMed/NCBI
18	Lu Y, Hu B, Guan GF, Chen J, Wang CQ, Ma Q, Wen YH, Qiu XC, Zhang XP and Zhou Y: SDF-1/CXCR4 promotes F5M2 osteosarcoma cell migration by activating the Wnt/β-catenin signaling pathway. Med Oncol. 32:1942015. View Article : Google Scholar : PubMed/NCBI
19	Song ZY, Gao ZH, Chu JH, Han XZ and Qu XJ: Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/β-catenin pathway in human colon cancer cells. Biomed Pharmacother. 71:46–52. 2015. View Article : Google Scholar : PubMed/NCBI
20	Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo H, Tian T, Ruan ZP, Kang XM, Wang J, et al: SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathway. Cancer Lett. 354:417–426. 2014. View Article : Google Scholar : PubMed/NCBI
21	Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet. 5:691–701. 2004. View Article : Google Scholar : PubMed/NCBI
22	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
23	Chen Z, Zhou L, Wang L, Kazobinka G, Zhang X, Han X, Li B and Hou T: HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/β-catenin signaling. Mol Carcinog. 57:12–21. 2018. View Article : Google Scholar : PubMed/NCBI
24	Yuan H, Yu S, Cui Y, Men C, Yang D, Gao Z, Zhu Z and Wu J: Knockdown of mediator subunit Med19 suppresses bladder cancer cell proliferation and migration by downregulating Wnt/β-catenin signalling pathway. J Cell Mol Med. 21:3254–3263. 2017. View Article : Google Scholar : PubMed/NCBI
25	Chan GK, Kleinheinz TL, Peterson D and Moffat JG: A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS One. 8:e635832013. View Article : Google Scholar : PubMed/NCBI
26	Bodart V, Anastassov V, Darkes MC, Idzan SR, Labrecque J, Lau G, Mosi RM, Neff KS, Nelson KL, Ruzek MC, et al: Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol. 78:993–1000. 2009. View Article : Google Scholar : PubMed/NCBI
27	Chen Y, Rao X, Huang K, Jiang X, Wang H and Teng L: FH535 inhibits proliferation and motility of colon cancer cells by targeting Wnt/β-catenin signaling pathway. J Cancer. 8:3142–3153. 2017. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Xu YC, Liang CJ, Zhang DX, Li GQ, Gao X, Fu JZ, Xia F, Ji JJ, Zhang LJ, Li GM, et al: : LncSHRG promotes hepatocellular carcinoma progression by activating HES6. Oncotarget. 8:70630–70641. 2017.PubMed/NCBI
30	Xie F, Xiang X, Huang Q, Ran P, Yuan Y, Li Q, Qi G, Guo X, Xiao C and Zheng S: Reciprocal control of lncRNA-BCAT1 and β-catenin pathway reveals lncRNA-BCAT1 long non-coding RNA acts as a tumor suppressor in colorectal cancer. Oncotarget. 8:23628–23637. 2017.PubMed/NCBI
31	Van Hout A, D'Huys T, Oeyen M, Schols D and Van Loy T: Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One. 12:e01760572017. View Article : Google Scholar : PubMed/NCBI
32	Rossi D and Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol. 18:217–242. 2000. View Article : Google Scholar : PubMed/NCBI
33	Muramaki M, Miyake H, Terakawa T, Kumano M, Sakai I and Fujisawa M: Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol. 30:161–166. 2012. View Article : Google Scholar : PubMed/NCBI
34	Olbert PJ, Kesch C, Henrici M, Subtil FS, Honacker A, Hegele A, Hofmann R and Hänze J: TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells. Urol Oncol. 33:110.e19–e27. 2015. View Article : Google Scholar
35	Yates TJ, Knapp J, Gosalbez M, Lokeshwar SD, Gomez CS, Benitez A, Ekwenna OO, Young EE, Manoharan M and Lokeshwar VB: C-X-C chemokine receptor 7: A functionally associated molecular marker for bladder cancer. Cancer. 119:61–71. 2013. View Article : Google Scholar : PubMed/NCBI
36	Wang H, Yang D, Wang K and Wang J: Expression and potential role of chemokine receptor CXCR4 in human bladder carcinoma cell lines with different metastatic ability. Mol Med Rep. 4:525–528. 2011.PubMed/NCBI
37	Shen CH, Wu JD, Jou YC, Cheng MC, Lin CT, Chen PC, Tseng YS, Shi CS, Chen SY, Chang DC, et al: The correlation between TWIST, E-cadherin, and beta-catenin in human bladder cancer. J BUON. 16:733–737. 2011.PubMed/NCBI
38	Nakopoulou L, Zervas A, Gakiopoulou-Givalou H, Constantinides C, Doumanis G, Davaris P and Dimopoulos C: Prognostic value of E-cadherin, beta-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res. 20:4571–4578. 2000.PubMed/NCBI
39	Du HF, Ou LP, Lv CK, Yang X, Song XD, Fan YR, Wu XH and Luo CL: Expression of hepaCAM inhibits bladder cancer cell proliferation via a Wnt/β-catenin-dependent pathway in vitro and in vivo. Cancer Biol Ther. 16:1502–1513. 2015. View Article : Google Scholar : PubMed/NCBI
40	Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu J: Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI
41	Vaid M, Prasad R, Sun Q and Katiyar SK: Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS One. 6:e230002011. View Article : Google Scholar : PubMed/NCBI
42	Ye W, Chen C, Gao Y, Zheng ZS, Xu Y, Yun M, Weng HW, Xie D, Ye S and Zhang JX: Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity. Cell Death Dis. 8:e25812017. View Article : Google Scholar : PubMed/NCBI
43	Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, et al: WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther. 8:458–468. 2009. View Article : Google Scholar : PubMed/NCBI
44	Gao Y, Guan Z, Chen J, Xie H, Yang Z, Fan J, Wang X and Li L: CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9. Int J Oncol. 47:690–700. 2015. View Article : Google Scholar : PubMed/NCBI
45	Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, Zhang L, Chen Y, Gao Y, Wang B, et al: Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal. 25:2625–2633. 2013. View Article : Google Scholar : PubMed/NCBI
46	Wang Z, Ma Q, Liu Q, Yu H, Zhao L, Shen S and Yao J: Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer. 99:1695–1703. 2008. View Article : Google Scholar : PubMed/NCBI
47	Liu Z, Hao C, Song D, Zhang N, Bao H and Qu Q: Androgen receptor coregulator CTBP1-AS is associated with polycystic ovary syndrome in Chinese Women: A preliminary study. Reprod Sci. 22:829–837. 2015. View Article : Google Scholar : PubMed/NCBI
48	Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F, Fusco A, Gutkind JS and Santoro M: The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res. 69:1867–1876. 2009. View Article : Google Scholar : PubMed/NCBI